The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F25%3A73632808" target="_blank" >RIV/61989592:15110/25:73632808 - isvavai.cz</a>

Result on the web

<a href="https://link.springer.com/content/pdf/10.1007/s12672-025-03792-6.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s12672-025-03792-6.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12672-025-03792-6" target="_blank" >10.1007/s12672-025-03792-6</a>

Result language

angličtina

Original language name

The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab

Original language description

The simultaneous occurrence of Hodgkin lymphoma (HL) and ovarian carcinoma(OC) is rare and presents unique challenges in diagnosis and treatment. Circulatingtumour DNA (ctDNA) offers a minimally invasive method for detecting minimalresidual disease in both malignancies. We present the case of a 42-year-old womanwith relapsed HL and advanced high-grade serous OC, treated with nivolumab, aPD-L1 inhibitor. After surgery and chemotherapy for OC, she received salvage therapyfor cHL, including autologous stem cell transplantation. During the therapy, thepatient was monitored using PET/CT and ctDNA analysis. CtDNA analysis detecteda Hodgkin-driven compound mutation in the STAT6 gene (N417Y/N421S) allowingearly relapse detection and treatment adjustments, detected progression of thedisease led to nivolumab initiation. The mutation was used to monitor minimalresidual disease (MRD). For ovarian carcinoma, presence of the BRAF V600E mutationas the marker was detected from archival paraffin-embedded ovarian tissue collectedat the time of diagnosis, during ctDNA monitoring, BRAF V600E associated with OCremained undetectable, aligning with remission. This case highlights the potentialof ctDNA to improve monitoring of concurrent malignancies, especially duringimmunotherapy, where PET/CT may lead to false-positive results. It is the firstreported case of nivolumab treatment for chemo-refractory relapsed HL and OC,demonstrating the utility of ctDNA in managing dual malignancies.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Discover Oncology

ISSN

2730-6011

e-ISSN

2730-6011

Volume of the periodical

16

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

2054

UT code for WoS article

001611571200003

EID of the result in the Scopus database

2-s2.0-105021123812